프리마켓
로그인 회원가입
FRNM
FRNM
🟢 신규
Freenome Inc
7월 27일 4:00 PM ET (한국 7/28 05:00)
$11.38
+0.14 ▲ +1.25%

FRNM is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독
시가총액
$117M
스몰캡
P/E
-
배당수익률
없음
52주 위치
32%
저점 +14% · 고점 -21%
애널리스트
-
F
Fundamental health
vs. Diagnostics & Research· based on 1 axes
수익성
산출 불가 (적자)
성장
데이터 부족
밸류에이션
데이터 부족
재무 안정
Top 95%
Index -P/E -EPS (ttm) -0.07Insider Own 30.95%Shs Outstand 8.2MPerf Week -4.77%
Market Cap 0.12BForward P/E -EPS next Y -Insider Trans -Shs Float 7.1MPerf Month 3.83%
Enterprise Value 0.12BPEG -EPS next Q -Inst Own -Short Float -Perf Quarter 0.09%
Income -0.00BP/S -EPS this Y -Inst Trans -Short Ratio -Perf Half Y -18.71%
Sales 0.00BP/B 1.49EPS next 5Y -ROA -0.86%Short Interest -Perf YTD -12.66%
Book/sh 7.64P/C 266.74EPS past 3/5Y -ROE -0.92%52W High -21.35% ($14.47)Perf Year 7.36%
Cash/sh 0.04P/FCF -Sales past 3/5Y -ROIC -0.97%52W Low 14.37% ($9.95)Perf 3Y -
Dividend Est. -EV/EBITDA -EPS Y/Y TTM -123.69%Gross Margin -Volatility(W/M) 15.02% 6.61%Perf 5Y -
Dividend TTM -EV/Sales -Sales Y/Y TTM -Oper. Margin -ATR (14) 0.85Perf 10Y -
Dividend Ex-Date -Quick Ratio 0.2EPS Q/Q -116.28%Profit Margin -RSI (14) 47.58Recom -
Dividend Gr. 3/5Y -Current Ratio 0.2Sales Q/Q -SMA20 -1.31% ($11.53)Beta 0.33Target Price -
Payout -Debt/Eq 0Earnings -SMA50 0.74% ($11.3)Rel Volume 8.61Prev Close $11.24
Employees 3LT Debt/Eq 0EPS/Sales Surpr. -SMA200 -2.9% ($11.72)Avg Volume(3M) 0.17MPrice $11.38
IPO 2024/6/12Option/Short No/YesTrades 3644Volume 1,448,844Change 1.25%
Quarterly earnings trend Quarterly earnings data is not yet available — foreign-listed companies (ADRs) only file annual reports with the U.S., and recently listed companies may not have filed their first quarterly report.

📊 Freenome Inc (FRNM) Investment Analysis

What kind of company is Freenome Inc?

Freenome Inc (FRNM) 방어주
Healthcare · Diagnostics & Research
Small-Cap — Low Volume, High Volatility

🧬 Prenom (FRNM) is a diagnostics and research company that uses artificial intelligence and multi-omics analysis to detect early-stage cancer through blood-based testing. Headquartered in California, USA, it is a micro-cap company developing a multi-cancer early detection platform, starting with colorectal cancer.

Learn more about Freenome Inc →
Market Cap
$0.1B
Approx. KRW 0.2 trillion
⚖️ 0% of Samsung Electronics
Market Cap Rank4460
Employees3people
IPO2024/06/12
Current Price$11.38 ≈ 15,591원
NASD · USA

Key Events

예정된 이벤트가 없습니다

FRNM의 다음 실적 발표일이나 배당 일정이 아직 수집되지 않았습니다.

  • 실적 발표는 보통 분기마다 있습니다
  • 배당주는 연 1~4회 배당락일이 있습니다
전체 경제/실적 캘린더 보기 →

Is it profitable?

Both profitability & finances need caution
Review management risk carefully before investing
Profitability — How efficiently it makes money
ROE
Annual return earned on shareholders' equity (15%+ is strong)
-0.9%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
ROA
Annual earnings relative to total company assets
-0.9%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
ROIC
Return generated per dollar invested in the business
-1.0%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
Financial health — Debt & liquidity burden
Debt-to-Equity (D/E)
Debt relative to equity (lower is healthier)
0.00
✓ Very low debt
My positionTop 5%
Low range Average High range
Diagnostics & Research Median 0.38
💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)
Current Ratio
Liquid assets available to cover liabilities due within a year
0.20
✓ 위험
💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의
Quick Ratio
Liquid assets excluding inventory, available for immediate use
0.20
✓ 위험
💡 1.0 이상이면 안전, 0.5 미만이면 주의
* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Outlook data is insufficient

Analyst estimates and price targets have not been collected.

Did earnings meet expectations?

Insufficient historical earnings data

No analyzable past earnings releases have been collected yet.

Has the stock risen over the long term?

Roughly in line with the market over the past year
FRNM +7.4% · S&P 500 +16.0%
Excess return vs. market (price-based, ex-dividends)
1-year basis
vs S&P 500
-8.7%p
slightly behind the market
vs Health Care (XLV)
-12.4%p
behind the sector average
Rank among peers
1-year return Upper-Mid (46%) Based on 14 peers
Current position within 52-week range
Low (-14.4%p) High (-21.4%p)
Current price is 14.4% above the 52-week low and 21.4% below the 52-week high

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

  • close
  • BB Upper
  • BB Mid
  • BB Lower
  • Tenkan
  • Kijun
  • Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🔴
Current diagnosis · 2026-07-27
Downtrend zone

Current price $11.38 below the midline ($11.53). Normal downward flow. Below the Ichimoku cloud (bearish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

Current diagnosis · 2026-07-27
Death cross — bearish reversal signal

MACD(0.226) crossed below Signal(0.230). Trend reversal possible; read as a sell entry point.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🔴
Current diagnosis · 2026-07-27
Bearish zone

RSI 47.6 (below the neutral level of 50). Selling pressure leads, indicating a weak trend. Stoch %K is also 33.2.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

Cheaper than peers in its industry
Cheap on Vs. Assets
💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.
🏢 Vs. Assets Cheap
🏢 Vs. Assets
PBR Price-to-Book Ratio
Price vs. the company's asset value — below 1 trades cheaper than assets
1.49x
✓ Very cheap
My positionTop 25%
Low range Average High range
Diagnostics & Research median 3.37x · Top 15% — relatively cheap within the industry
💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)
* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.
As of: Recent snapshot · Peer group: Diagnostics & Research

Who owns it?

Ownership is broadly stable
📈 Recent trading flow (6 months)
🧑‍💼 Insiders (executives & directors)
0.0%
Insiders little change
🏦 Institutions (funds & investors)
-
No trading data for Institutions
💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.
👥 Holdings composition
🧑‍💼 Insiders 30.9%
Founder/management large holders (strong skin-in-the-game)
Healthcare 초소형주 Median 16.1%
👤 Retail investors (estimated) 69.0%
Everyone excluding institutions and insiders
Institutions Insiders Retail (est.)
🧮 Share count
Total shares outstanding 8.2M주
Float (tradable shares) 7.1M주
* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 0 days.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)
Sorted by market cap, largest first
StockMarket CapPERPBRROEDividend YieldChange
FRNM FRNM This Stock
$117.4M- 1.5 -0.92% - +1.3%
LLY
$1.13T43.1 36.2 107.64% 0.58% +0.1%
JNJ
$640.9B30.8 7.5 25.74% 2.02% +1.0%
ABBV
$453.9B126.7 - 15221.82% 2.67% -0.9%
UNH
$379.3B26.9 3.9 12.49% 2.16% -0.7%
MRK
$323.0B36.8 7.0 18.97% 2.5% -0.2%
Sector Avg-26.12.7-48.83%1.23%-
📊
See the market at a glance with a real-time dashboard Track premarket, regular, and after-hours quotes, screeners, and heatmaps on a single screen

FAQ

What kind of company is FRNM?

FRNM belongs to the Healthcare sector and operates in the Diagnostics & Research industry.

What is the market cap of FRNM?

The market cap of FRNM is approximately $117M, ranking 4,460 within its sector.

What is the 52-week high and low for FRNM?

FRNM has recorded a 52-week high of $14.47 and a low of $9.95.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.